Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test synthetic nicotine and new Nicotine-Like chemicals in vapers

NCT ID NCT07348224

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 6 times

Summary

This study will compare how synthetic nicotine and a nicotine analogue (6-methylnicotine) behave in the body versus traditional tobacco-derived nicotine. Twenty-four regular vapers will vape e-liquids containing these substances, and researchers will measure their levels in the blood and their effects. The goal is to understand if these newer products work the same way as standard nicotine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
synthetic nicotine (S-nicotine, racemic nicotine) and nicotine analogue 6-methylnicotine
What this could lead to
If successful, this could clarify whether synthetic nicotine and nicotine analogues work like traditional nicotine, informing regulation and product safety.
What could go wrong
This is a small, early-phase study (24 people) that only measures short-term effects. Results may not apply to long-term use or broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women, age 18 or older at screening who have used EC with nicotine during at least 10 of the past 30 days * Saliva cotinine concentration of \> 30 ng/mL at screening * Ability to communicate well with the investigator and to understand and comply with the requirements of the study * Women of child-bearing age engaging in sexual activities which can lead to pregnancy: willingness of using a reliable/hormonal contraception method during the study (hormonal, e.g. pill, intrauterine devices, or mechanical method, e.g. condom, diaphragm) * Signed informed consent form Exclusion Criteria: * Known hypersensitivity/allergy to a content of the e-liquids * Smoking of more than 5 cigarettes per day in the past 30 days * Pregnant or lactating women * Intention to become pregnant during the course of the study * BMI \< 18 or \> 30 kg/m2 at screening * History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening * Loss of ≥ 250 mL of blood within 3 months prior to screening, including blood donation * Treatment with an investigational drug within 30 days prior to screening * Treatment with prescribed or over-the-counter medications with known influence on CYP2A6 function within 1 week prior to screening (with the exception of contraception) * History or clinical evidence of any disease (e.g. gastrointestinal tract-disease) and/or existence of any surgical or medical condition, which in the opinion of the investigator might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk of toxicity. * Legal incapacity or limited legal capacity at screening * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nicotine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Inselspital

    RECRUITING

    Bern, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.